2. Academic Validation
  3. Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts

Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts

  • Am J Nucl Med Mol Imaging. 2015 Oct 12;5(5):493-503.
David E Gerber 1,  Guiyang Hao 2,  Linda Watkins 3,  Jason H Stafford 4,  Jon Anderson 2,  Blair Holbein 5,  Orhan K Öz 2,  Dana Mathews 2,  Philip E Thorpe 6,  Gedaa Hassan 2,  Amit Kumar 2,  Rolf A Brekken 7,  Xiankai Sun 8
Affiliations

Affiliations

  • 1 Division of Hematology-Oncology, University of Texas Southwestern Medical Center Dallas, Texas 75390-8852, USA ; Department of Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center Dallas, Texas 75390-8852, USA.
  • 2 Department of Radiology, University of Texas Southwestern Medical Center Dallas, Texas 75390-8852, USA.
  • 3 Department of Pharmacology, University of Texas Southwestern Medical Center Dallas, Texas 75390-8852, USA.
  • 4 Department of Pharmacology, University of Texas Southwestern Medical Center Dallas, Texas 75390-8852, USA ; Current Address: Stanford University Medical Center USA.
  • 5 Department of Clinical Sciences, University of Texas Southwestern Medical Center Dallas, Texas 75390-8852, USA.
  • 6 Department of Pharmacology, University of Texas Southwestern Medical Center Dallas, Texas 75390-8852, USA ; Department of Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center Dallas, Texas 75390-8852, USA.
  • 7 Department of Surgery, University of Texas Southwestern Medical Center Dallas, Texas 75390-8852, USA ; Department of Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center Dallas, Texas 75390-8852, USA.
  • 8 Department of Radiology, University of Texas Southwestern Medical Center Dallas, Texas 75390-8852, USA ; Department of Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center Dallas, Texas 75390-8852, USA.
PMID: 26550540
Abstract

Bavituximab is a chimeric monoclonal antibody with immune modulating and tumor-associated vascular disrupting properties demonstrated in models of non-small cell lung Cancer (NSCLC). The molecular target of Bavituximab, phosphatidylserine (PS), is exposed on the outer leaflet of the membrane bi-layer of malignant vascular endothelial cells and tumor cells to a greater extent than on normal tissues. We evaluated the tumor-targeting properties of Bavituximab for imaging of NSCLC xenografts when radiolabeled with (111)In through conjugation with a bifunctional chelating agent, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). In vitro binding of (111)In-DOTA-Bavituximab to PS was determined by enzyme-linked immunosorbent assay (ELISA). Biodistribution of (111)In-DOTA-Bavituximab was conducted in normal rats, which provided data for dosimetry calculation. Single-photon emission computed tomography/computed tomography (SPECT/CT) imaging was performed in athymic nude rats bearing A549 NSCLC xenografts. At the molar conjugation ratio of 0.54 DOTA per Bavituximab, the PS binding affinity of (111)In-DOTA-Bavituximab was comparable to that of unmodified Bavituximab. Based on the quantitative SPECT/CT imaging data analysis, (111)In-DOTA-Bavituximab demonstrated tumor-specific uptake as measured by the tumor-tomuscle ratio, which peaked at 5.2 at 72 hr post-injection. In contrast, the control antibody only presented a contrast of 1.2 at the same time point.These findings may underlie the diagnostic efficacy and relative low rates of systemic vascular and immune-related toxicities of this immunoconjugate. Future applications of (111)In-DOTA-bavituximab may include prediction of efficacy, indication of tumor immunologic status, or characterization of radiographic findings.

Keywords

111In; Bavituximab; immunotherapy; lung cancer; phosphatidylserine; vascular targeting.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z